[Skip to Content]
[Skip to Content Landing]
Views 1,158
Citations 0
Editorial
February 12, 2020

Sexual and Gender Minority Populations and Skin Cancer—New Data and Renewed Priorities

Author Affiliations
  • 1Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
  • 2Regional Telehealth Service, Virginia Southeast Network VISN 7, Decatur, Georgia
  • 3Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
JAMA Dermatol. Published online February 12, 2020. doi:10.1001/jamadermatol.2019.4174

Sexual and gender minority (SGM) persons include, but are not limited to, individuals who identify as lesbian, gay, bisexual, or transgender, as well as individuals whose sexual orientation, gender identity or expression, or reproductive development are characterized by nonbinary constructs of sexual orientation, gender, and/or sex.1 The National Cancer Institute (NCI) has called for specific research to “assess cancer risk to inform improved decision-making, risk reduction interventions, and screening options for early cancer detection in SGM populations.”1 Notably, population-based data on skin cancer epidemiology in SGM persons remain inadequate. Without robust epidemiologic data, it has been challenging for dermatologists to recognize and articulate their specific roles within broader national conversations on improving SGM health. Emerging skin cancer data, particularly among gay and bisexual men, indicate unmet needs for skin cancer prevention in specific SGM subpopulations.2

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×